ライフサイエンスコーパス: tissue inhibitor of metalloproteinase

1 e metalloproteinase interaction sites of the tissue inhibitors of metalloproteinases.

2 alloproteinases in a manner analogous to the tissue inhibitors of metalloproteinases.

3 MPs) is relatively unopposed by the specific tissue inhibitors of metalloproteinases.

4 transforming growth factor beta1 (P=0.0004), tissue inhibitor of metalloproteinase 1 (P=0.0009), gran

5 oteinase 9 (MMP-9) and increased circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) and TIM

6 91(phox(-/-) ) than in WT mice after CCl(4.) Tissue inhibitor of metalloproteinase 1 (TIMP-1) and TIM

7 Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a st

8 including COX-2 itself, lipocalin 2 (LCN2), tissue inhibitor of metalloproteinase 1 (TIMP-1), interl

9 expression of fibrogenic genes IL-1beta and tissue inhibitor of metalloproteinase 1 (TIMP-1), with t

10 Tissue inhibitor of metalloproteinase 1 (TIMP-1)-deficie

11 oducts (collagen type 1 alpha 1 (CoL1A1) and tissue inhibitor of metalloproteinase 1 (TIMP1)) were al

12 Herein, we demonstrate that tissue inhibitor of metalloproteinase 1 (TIMP1), a secre

13 8 (IL-8), human beta-defensin 1 (hBD-1), and tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 an

14 MP-1 was up-regulated, whereas expression of tissue inhibitor of metalloproteinase 1 decreased before

15 factor-beta1, alpha-smooth muscle actin, and tissue inhibitor of metalloproteinase 1 expression and a

16 ries of Dicer(d/d) mice partially normalized tissue inhibitor of metalloproteinase 1 expression and C

17 s after biliary decompression, both MMP3 and tissue inhibitor of metalloproteinase 1 expression decli

18 ate cells (HSCs) were activated and produced tissue inhibitor of metalloproteinase 1 in a sphingosine

19 the eye, and the imbalance between MMP-1 and tissue inhibitor of metalloproteinase 1 may play a role

20 broblasts, reduced hepatic procollagen I and tissue inhibitor of metalloproteinase 1 messenger RNA ex

21 flammation (C-reactive protein, soluble ST2, tissue inhibitor of metalloproteinase 1).

22 , including transforming growth factor beta, tissue inhibitor of metalloproteinase 1, and connective

23 Serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and procollagen

24 ns of prostaglandin-endoperoxide synthase 2, tissue inhibitor of metalloproteinase 1, Dpp4, nitric ox

25 increased messenger RNA levels of collagen, tissue inhibitor of metalloproteinase 1, matrix metallop

26 reases levels of their endogenous inhibitor, tissue inhibitor of metalloproteinase 1, resulting in ma

27 d in increased expression of MMP3, MMP8, and tissue inhibitor of metalloproteinase 1.

28 the expression of the antiangiogenic factor tissue inhibitor of metalloproteinase 1.

29 Tissue inhibitor of metalloproteinases 1 (TIMP-1) is a m

30 Matrix metalloproteinase 3 (MMP-3) and tissue inhibitor of metalloproteinases 1 (TIMP-1) messen

31 lloproteinase 1 [MMP-1], MMP-13, and MMP-3), tissue inhibitor of metalloproteinases 1 (TIMP-1), and c

32 smosine, matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), and T

33 d wine and ethanol upregulated expression of tissue inhibitor of metalloproteinases 1 (TIMP-1), downr

34 invasion assay in the presence or absence of tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-

35 r metalloproteinase 2 (MMP-2), MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-

36 explants induced synthesis and secretion of tissue inhibitor of metalloproteinases 1 (TIMP-1), which

37 faip6), matrix metalloproteinase 19 (Mmp19), tissue inhibitor of metalloproteinases 1 (Timp1), and po

38 MMP-9), and the inhibitors of these enzymes (tissue inhibitor of metalloproteinases 1 [TIMP-1] and TI

39 prometastatic matrix metalloproteinase 8 and tissue inhibitor of metalloproteinases 1 in metastatic n

40 DAMTS-5 increased approximately 40-fold, and tissue inhibitor of metalloproteinases 1 increased appro

41 mor necrosis factor receptor 2 or IL-10, and tissue inhibitor of metalloproteinases 1) were identifie

42 st up-regulated genes (e.g., caspase-3, p21, tissue inhibitor of metalloproteinases 1, 2, and 3, and

43 ulmonary and activation-regulated chemokine, tissue inhibitor of metalloproteinases 1, and soluble CD

44 scores with the lowest levels of IFN-alpha, tissue inhibitor of metalloproteinases 1, and vascular e

45 enic factors (eg, ANG [angiogenin], TIMP1/2 [tissue inhibitor of metalloproteinases 1/2], and RANTES

46 kin 6 [IL-6]; stromal cell-derived factor 1; tissue inhibitor of metalloproteinases 1; and vascular c

47 3 (IL-23), IL-1 receptor I (IL-1RI), IL-17R, tissue inhibitors of metalloproteinase 1 and 2 (TIMP-1 a

48 Tissue inhibitors of metalloproteinase 1 and 4 gene expr

49 increased in TAA tissue homogenates, whereas tissue inhibitors of metalloproteinases 1 and 4 decrease

50 03), MMP-2 (p = 0.06), MMP-3 (p = 0.02), and tissue inhibitor of metalloproteinase-1 (p = 0.04) in el

51 is substantially resistant to inhibition by tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIM

52 TNFalpha, but not IGF-I, induced tissue inhibitor of metalloproteinase-1 (TIMP-1) express

53 Exogenous tissue inhibitor of metalloproteinase-1 (TIMP-1) has a g

54 Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an e

55 Tissue inhibitor of metalloproteinase-1 (TIMP-1) is the

56 lagen I type I, fibronectin, COL1alpha1, and tissue inhibitor of metalloproteinase-1 (TIMP-1) were in

57 treated with IL-1beta express high levels of tissue inhibitor of metalloproteinase-1 (TIMP-1), an imp

58 rix metalloproteinase-2 and 9 (MMP-2 and 9), tissue inhibitor of metalloproteinase-1 (TIMP-1), macrop

59 who underwent routine measurements of plasma tissue inhibitor of metalloproteinase-1 (TIMP-1), metall

60 sults, in part, from increased expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), which

61 ted in an increase in expression of the gene tissue inhibitor of metalloproteinase-1 (TIMP-1).

62 genes that exhibit compatible kinetics, e.g. tissue inhibitor of metalloproteinase-1 (TIMP-1).

63 oteinase-9 (MMP-9) and reduced expression of tissue inhibitor of metalloproteinase-1 (TIMP-1).

64 smooth muscle actin (alphaSMA), collagen I, tissue inhibitor of metalloproteinase-1 (TIMP1) and tran

65 The tissue inhibitor of metalloproteinase-1 (TIMP1) is expre

66 -type plasminogen activator while increasing tissue inhibitor of metalloproteinase-1 and plasminogen

67 teinase-2 and -9 but was linked to decreased tissue inhibitor of metalloproteinase-1 and plasminogen

68 th a balance between metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 expressions.

69 ase-8 expression and decreased expression of tissue inhibitor of metalloproteinase-1 in pulmonary acu

70 By contrast, levels of mRNA for tissue inhibitor of metalloproteinase-1 in the transfect

71 llagen content and an increase in myocardial tissue inhibitor of metalloproteinase-1 levels.

72 , whereas vascular expression of collagen or tissue inhibitor of metalloproteinase-1 were down-regula

73 owth factor receptor beta, desmin, vimentin, tissue inhibitor of metalloproteinase-1) and fibrosis (r

74 and Lix/CXCL-5), matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and apoptosis r

75 s syndrome); and matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1, and CXCL13 in A

76 Sputum neutrophil elastase, tissue inhibitor of metalloproteinase-1, and TNF-alpha i

77 with gene expression for alpha2(I) collagen, tissue inhibitor of metalloproteinase-1, and transformin

78 n expression of MMP-1, collagen type 1alpha, tissue inhibitor of metalloproteinase-1, and vascular re

79 nogen activator inhibitor (PAI)-1, vimentin, tissue inhibitor of metalloproteinase-1, fibronectin, gr

80 ic responses in HSCs, including secretion of tissue inhibitor of metalloproteinase-1.

81 l mRNA levels of aggrecan, collagen IIa, and tissue inhibitor of metalloproteinase-1.

82 with a concomitant decrease in expression of tissue inhibitor of metalloproteinase-1.

83 f 4) and truncation is completely blocked by tissue inhibitor of metalloproteinase-1.

84 In contrast, the expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) and co

85 The regulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) by UDC

86 Increasing evidence suggests that tissue inhibitor of metalloproteinases-1 (TIMP-1) can di

87 is via its transcriptional regulation of the tissue inhibitor of metalloproteinases-1 (TIMP-1) gene.

88 role in extracellular matrix remodeling, the tissue inhibitor of metalloproteinases-1 (TIMP-1) has be

89 In astrocytes, the expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) is up-

90 Serum tissue inhibitor of metalloproteinases-1 (TIMP-1) levels

91 Tissue inhibitor of metalloproteinases-1 (TIMP-1) recent

92 ase their proMMP-9 in a unique form, free of tissue inhibitor of metalloproteinases-1 (TIMP-1).

93 Tissue inhibitor of metalloproteinases-1 (TIMP1) creates

94 al injury including Cystatin C, Osteopontin, Tissue Inhibitor of Metalloproteinases-1 (TIMP1), beta2-

95 Apolipoprotein E and tissue inhibitor of metalloproteinases-1 knockout mice (

96 protein-10 (IP-10), interleukin (IL)-6, and tissue inhibitor of metalloproteinases-1 on days 8-9 aft

97 to analyze serum levels of hyaluronic acid, tissue inhibitor of metalloproteinases-1, and propeptide

98 the expression of its natural inhibitor, the tissue inhibitor of metalloproteinases-1.

99 metalloproteinase-2, and increased levels of tissue inhibitors of metalloproteinase-1 and -2.

100 The ECM did not affect the secretion of tissue inhibitors of metalloproteinases-1 or -2.

101 Tissue inhibitor of metalloproteinase 2 (TIMP-2) is an a

102 aneously increasing tissue inhibitor of MMP (tissue inhibitor of metalloproteinase 2).

103 ating factor, stromal cell-derived factor-1, tissue inhibitor of metalloproteinase 2, and von Willebr

104 rofibrotic (transforming growth factor beta, tissue inhibitor of metalloproteinase 2, collagen type I

105 E cells, without affecting the expression of tissue inhibitor of metalloproteinase 2.

106 proteinases (MT1-MMP) in the presence of the tissue inhibitor of metalloproteinases 2 (TIMP2) in a bu

107 Tissue inhibitor of metalloproteinases 2 (TIMP2), a bloo

108 ulinlike growth factor-binding protein 7 and tissue inhibitor of metalloproteinases 2 after surgery (

109 urnover: matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 2, C-terminal typ

110 tor GM6001 or the specific MT1-MMP inhibitor tissue inhibitor of metalloproteinases 2.

111 ling was associated with decreased levels of tissue inhibitors of metalloproteinase 2, -3, and -4 and

112 nd MMP19, and increased transcript levels of tissue inhibitors of metalloproteinase 2.

113 The endothelial cell (EC)-derived tissue inhibitor of metalloproteinase-2 (TIMP-2) and per

114 nase-2/-9 exhibited little change, the large tissue inhibitor of metalloproteinase-2 (TIMP-2) increas

115 zymography), and cellular contents of MMP2, tissue inhibitor of metalloproteinase-2 (TIMP2), and pho

116 Performance of the tissue inhibitor of metalloproteinase-2 and insulin-like

117 r operating characteristic curve (95% CI) of tissue inhibitor of metalloproteinase-2 and insulin-like

118 the effect of nonrenal organ dysfunction on tissue inhibitor of metalloproteinase-2 and insulin-like

119 for each patient on enrollment and compared tissue inhibitor of metalloproteinase-2 and insulin-like

120 Urinary tissue inhibitor of metalloproteinase-2 and insulin-like

121 We observed significantly higher urine tissue inhibitor of metalloproteinase-2 and insulin-like

122 In multivariate analysis, the addition of tissue inhibitor of metalloproteinase-2 and insulin-like

123 he performance of the model with and without tissue inhibitor of metalloproteinase-2 and insulin-like

124 nfirmed the involvement of the MT1-MMP/MMP-2/tissue inhibitor of metalloproteinase-2 complex in this

125 We also evaluated MT1-MMP, MMP-2, and tissue inhibitor of metalloproteinase-2 expression in se

126 fibronectin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-2 was studied with

127 these, matrix metalloproteinase-2 (MMP2) and tissue inhibitor of metalloproteinase-2 were down-regula

128 oMTb decreased expression of the inhibitors, tissue inhibitor of metalloproteinase-2, -3, and -4.

129 ne domain in the biosensor or treatment with tissue inhibitor of metalloproteinase-2, a cell-impermea

130 a membrane-associated factor, inhibited with tissue inhibitor of metalloproteinase-2, and abolished w

131 content, potentially through an increase in tissue inhibitor of metalloproteinase-2, and transmigrat

132 inhibition of proMMP-2 cleavage; recombinant tissue inhibitor of metalloproteinase-2, which binds to

133 crossed with transgenic mice overexpressing tissue inhibitor of metalloproteinase-2-a natural MMP in

134 alloproteinase-2 and increased expression of tissue inhibitor of metalloproteinase-2.

135 Tissue inhibitor of metalloproteinases-2 (TIMP-2) is a b

136 The tissue inhibitor of metalloproteinases-2 (TIMP-2) is kno

137 an archetype member of the MMP family, binds tissue inhibitor of metalloproteinases-2 (TIMP-2), activ

138 forming growth factor-beta3 (TGF-beta3), and tissue inhibitor of metalloproteinases-2 (TIMP-2).

139 ne with its physiological protein inhibitor, tissue inhibitor of metalloproteinases-2 (TIMP-2).

140 , membrane type 1-MMP (MT1-MMP, MMP-14), and tissue inhibitor of metalloproteinases-2 (TIMP-2).

141 In the double MMTV-Wnt1/tissue inhibitor of metalloproteinases-2 transgenic mice

142 ercellular adhesion molecule-1, eotaxin, and tissue inhibitor of metalloproteinases-2.

143 t activation of pro-MMP-2 in the presence of tissue inhibitor of metalloproteinases-2.

144 ic response in human articular chondrocytes, tissue inhibitor of metalloproteinase 3 (TIMP-3) inducti

145 The tissue inhibitor of metalloproteinase 3 (TIMP-3) is esse

146 ically, d-flow-induced miR-712 downregulates tissue inhibitor of metalloproteinase 3 (TIMP3) expressi

147 Herein, we show that ITGA7 binds to tissue inhibitor of metalloproteinase 3 (TIMP3) in prost

148 1 (ADAMTS1) and downregulated its inhibitor, tissue inhibitor of metalloproteinase 3 (TIMP3) in respo

149 Acrolein increased MMP9 and decreased tissue inhibitor of metalloproteinase 3 (TIMP3), an endo

150 in natural regulator of TACE activity is the tissue inhibitor of metalloproteinase 3 (Timp3), we hypo

151 e-wide association study; the locus near the tissue inhibitor of metalloproteinase 3 was corroborated

152 TIMP3 (tissue inhibitor of metalloproteinase 3) accumulation in

153 ecanase activity with monoclonal antibodies, tissue inhibitor of metalloproteinases 3 (TIMP-3), and c

154 recognized aggrecanases and their inhibitor, tissue inhibitor of metalloproteinases 3 (TIMP-3), in hu

155 Tissue inhibitor of metalloproteinases 3 (TIMP3) control

156 Tissue inhibitor of metalloproteinases 3 (TIMP3) inhibit

157 We hypothesised that in health, tissue inhibitor of metalloproteinases 3 (TIMP3) modulat

158 We generated oHSVs that express human tissue inhibitor of metalloproteinases 3 (TIMP3) or fire

159 evels of programmed cell death 4 (PDCD4) and tissue inhibitor of metalloproteinases 3 (TIMP3).

160 ents with active AAV, but those of ADAM10 or tissue inhibitor of metalloproteinases 3, which inhibits

161 the endogenous inhibitor of metalloproteases tissue inhibitors of metalloproteinase 3 (TIMP3).

162 se inhibitor-2 (TAPI-2), phenanthroline, and tissue inhibitor of metalloproteinase-3 (TIMP-3) but not

163 Tissue inhibitor of metalloproteinase-3 (TIMP-3) is a du

164 ogenic effects by upregulating expression of tissue inhibitor of metalloproteinase-3 (TIMP3) in a P53

165 ssion events by delivering molecules such as tissue inhibitor of metalloproteinase-3 and angiopoietin

166 afforded by miR-181b inhibition are largely tissue inhibitor of metalloproteinase-3 dependent, while

167 To investigate whether miR-181b regulates tissue inhibitor of metalloproteinase-3 expression and a

168 hat miR-181b negatively regulates macrophage tissue inhibitor of metalloproteinase-3 expression and v

169 ive CXCR2 ligand GROalpha (10 ng/ml) induced tissue inhibitor of metalloproteinase-3 expression, mark

170 We additionally show that tissue inhibitor of metalloproteinase-3, an inhibitor of

171 ed expression of predicted miR-181b targets, tissue inhibitor of metalloproteinase-3, and elastin.

172 ed expression of predicted miR-181b targets, tissue inhibitor of metalloproteinase-3, and elastin.

173 l-specific molecule-1, 5'-ecto-nucleotidase, tissue inhibitor of metalloproteinase-3, epidermal growt

174 uble Pref-1A is inhibited by TAPI-0 and by a tissue inhibitor of metalloproteinase-3, TIMP-3, that ca

175 icant reduction of its endogenous inhibitor, tissue inhibitor of metalloproteinase-3.

176 Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a c

177 Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a m

178 Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a m

179 Tissue Inhibitor of metalloproteinases-3 (TIMP-3) is a p

180 Tissue inhibitor of metalloproteinases-3 (TIMP-3) plays

181 ddition, CaPPS increased cartilage levels of tissue inhibitor of metalloproteinases-3 (TIMP-3), an en

182 aused by mutations in exon 5 of the gene for tissue inhibitor of metalloproteinases-3 (TIMP-3).

183 ith pan-metalloproteinase inhibitors or with tissue inhibitors of metalloproteinase-3 reduced neurite

184 yl oxidase, adamalysin metalloproteinase-17, tissue inhibitors of metalloproteinase-3, c-Met and CXCR

185 To quantify the levels of tissue inhibitor of metalloproteinase 4 (TIMP4) and its

186 ls exhibit significantly decreased levels of tissue inhibitor of metalloproteinases 4 (TIMP-4).

187 trix metalloproteinase-2 (MMP-2), MMP-9, and tissue inhibitor of metalloproteinase-4 (TIMP-4) in lung

188 and alterations in matrix metalloproteinase/tissue inhibitors of metalloproteinase abundance, consis

189 Accurate K(i) values for tissue inhibitors of metalloproteinase and small molecul

190 Tissue inhibitors of metalloproteinases and a specific p

191 jor regulators of MMP-2 activity such as the tissue inhibitors of metalloproteinases and MMP-14.

192 e MMP-9 much less sensitive to inhibition by tissue inhibitors of metalloproteinases and synthetic in

193 cium-binding S100, matrix metalloproteinase, tissue inhibitor of metalloproteinase, and ion channel f

194 ring wing maturation, the Timp gene product, tissue inhibitor of metalloproteinases, and probably oth

195 reduced, pulmonary expression of collagens, tissue inhibitors of metalloproteinases, and fibrogenic

196 hich was caused by the reduced expression of tissue inhibitors of metalloproteinases as well as incre

197 ion of selected matrix metalloproteinases or tissue inhibitors of metalloproteinases between the woun

198 proteins (eg, matrix metalloproteinases and tissue inhibitor of metalloproteinases) compared with wi

199 lated by M. tuberculosis, and no increase in tissue inhibitor of metalloproteinase expression occurs

200 expression and activity; and (c) stimulated tissue inhibitor of metalloproteinase expression.

201 isintegrin and metalloproteinase domain, and tissue inhibitors of metalloproteinases in M. tuberculos

202 hibition of metalloproteinases in mice using tissue inhibitors of metalloproteinases increases plaque

203 emically characterized MT6-MMP, profiled its tissue inhibitor of metalloproteinase inhibitory spectru

204 reover, small but significant alterations in tissue inhibitors of metalloproteinase levels also occur

205 otoxin variants or suggested by analogy with tissue inhibitors of metalloproteinases, progressively e

206 effects dependent on increased expression of tissue inhibitor of metalloproteinase-sensitive protease

207 inally, studies that either removed or added tissue inhibitor of metalloproteinases species in the my

208 1, matrix metalloproteinase (MMP)-2, MMP-14, tissue inhibitor of metalloproteinase (TIMP) -1, and TIM

209 and activity, concomitant with increases in tissue inhibitor of metalloproteinase (TIMP) 1 and E-cad

210 Conversely, Ad-MMP-2-Si-CM induced tissue inhibitor of metalloproteinase (TIMP) 3 expressio

211 radation, matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) expression,

212 hemokine, and matrix metalloproteinase (MMP)/tissue inhibitor of metalloproteinase (TIMP) expression.

213 it differential inhibition by members of the tissue inhibitor of metalloproteinase (TIMP) family.

214 BARX2 also increases the expression of the tissue inhibitor of metalloproteinase (TIMP) genes, TIMP

215 ray Human MMP/TIMP Array to quantify MMP and tissue inhibitor of metalloproteinase (TIMP) production

216 between matrix metalloproteinase (MMP)-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and -2 an

217 In contrast, tissue inhibitor of metalloproteinase (TIMP)-1 and -2 se

218 ocyte chemoattractant protein (MCP)-1, IL-8, tissue inhibitor of metalloproteinase (TIMP)-1 and -2, a

219 increased the protein levels of HIF-1alpha, tissue inhibitor of metalloproteinase (TIMP)-1 and colla

220 ysis of matrix metalloproteinase (MMP)-8 and tissue inhibitor of metalloproteinase (TIMP)-1 by enzyme

221 Tissue inhibitor of metalloproteinase (TIMP)-1 expressio

222 Low exogenous NO perturbed MMP/tissue inhibitor of metalloproteinase (TIMP)-1 levels by

223 We hypothesized that overexpression of tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2

224 In addition, during SIBO, MMP-1, tissue inhibitor of metalloproteinase (TIMP)-1, and TIMP

225 e activation states of hepatic MMP-9, MMP-2, tissue inhibitor of metalloproteinase (TIMP)-1, TGF-beta

226 lysis revealed a selective downregulation of tissue inhibitor of metalloproteinase (TIMP)-2 in PmAF a

227 xpression of fibrin, collagen, TGF-beta, and tissue inhibitor of metalloproteinase (TIMP)-2 increased

228 mall interfering RNA suppression of pericyte tissue inhibitor of metalloproteinase (TIMP)-3 (a known

229 ition of TACE activity by specific inhibitor tissue inhibitor of metalloproteinase (TIMP)-3 at dosage

230 Tissue inhibitor of metalloproteinase (Timp)-3 effective

231 s of the matrix metalloproteinase inhibitor, tissue inhibitor of metalloproteinase (TIMP)-4, are asso

232 t growth factor (FGF)-3, its receptor FGFR3, tissue inhibitor of metalloproteinase (TIMP)-4, laminin

233 MP-9 enzyme were critically dependent on the tissue inhibitor of metalloproteinase (TIMP)-free status

234 The tissue inhibitor of metalloproteinase (TIMP)3, a stromal

235 (uPA), matrix metalloproteinase (MMP)14, and tissue inhibitor of metalloproteinase (TIMP-2) were cons

236 This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the c

237 if neutrophil proMMP-9, naturally devoid of tissue inhibitor of metalloproteinases (TIMP), was deliv

238 bit prometastatic matrix metalloproteinases, tissue inhibitor of metalloproteinases (TIMP)-1 has been

239 terleukin 8, hepatocyte growth factor (HGF), tissue inhibitor of metalloproteinases (TIMP)-1, and E-s

240 Here we report that tissue inhibitor of metalloproteinases (TIMP)-2 and TIMP

241 O), and matrix metalloproteinase (MMP)-2 and tissue inhibitor of metalloproteinases (TIMP)-2 complex.

242 -molecular complex of pro-MMP-2, MMP-14, and tissue inhibitor of metalloproteinases (TIMP)-2.

243 Tissue inhibitor of metalloproteinases (TIMP)-3 is an in

244 Tissue inhibitor of metalloproteinases (TIMP)-3, an endo

245 the endogenous metalloproteinase inhibitor, tissue inhibitor of metalloproteinases (TIMP)-3, through

246 Their main endogenous inhibitor is tissue inhibitor of metalloproteinases (TIMP)-3.

247 utrophil proMMP-9 required activation of the tissue inhibitor of metalloproteinases (TIMP)-free zymog

248 antitative real-time PCR analysis, levels of tissue inhibitor of metalloproteinases (TIMP-1 and TIMP-

249 , i.e., MMP-9 and MMP-2, and upregulation of tissue inhibitors of metalloproteinase (TIMP) -1 and TIM

250 P. acnes induced the mRNA expression of tissue inhibitors of metalloproteinase (TIMP)-1, the mai

251 including CD34MVD, EMA, p21ras, p21WAF1, and tissue inhibitors of metalloproteinases (TIMP) -2.

252 balance between metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) has been

253 Previous studies have shown that the tissue inhibitors of metalloproteinases (TIMP)-2 gene, w

254 ilizing a rat model of lung transplantation, tissue inhibitors of metalloproteinases (TIMP-1 and TIMP

255 ted lipocalin, cystatin C, trefoil factor 3, tissue inhibitor of metalloproteinase [TIMP]-1, and beta

256 trix metalloproteinases (MMPs 12 and 13) and tissue inhibitor of metalloproteinases (TIMP1), as well

257 talloproteinase MMP2, in the presence of the tissue inhibitor of metalloproteinases TIMP2, constitute

258 ix metalloproteinases (MMPs) 1, 2, 3, and 9; tissue inhibitor of metalloproteinases (TIMPs) 1, 2, and

259 ed MT6-MMPs were found to be associated with tissue inhibitor of metalloproteinases (TIMPs) and did n

260 Tissue inhibitor of metalloproteinases (TIMPs) are the e

261 Tissue inhibitor of metalloproteinases (TIMPs) protect t

262 e expression of their natural inhibitor, the tissue inhibitor of metalloproteinases (TIMPs), are pote

263 , we profiled MMPs and their inhibitors, the tissue inhibitor of metalloproteinases (TIMPs), in sputu

264 pression of MT1-MMP in ECs or by addition of tissue inhibitor of metalloproteinases (TIMPs)-2, -3, an

265 We have found that LPA downregulates tissue inhibitor of metalloproteinases (TIMPs).

266 the case of the natural inhibitors of MMPs, tissue inhibitor of metalloproteinases (TIMPs).

267 derived matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) in cancer

268 MMP10, MMP13, and trypsin; inhibition by the tissue inhibitors of metalloproteinases (TIMPs) 1 and 2;

269 x metalloproteinases (MMPs) 1, 3, and 13 and tissue inhibitors of metalloproteinases (TIMPs) 1 and 3

270 Tissue inhibitors of metalloproteinases (TIMPs) are a fa

271 Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are invo

272 Tissue inhibitors of metalloproteinases (TIMPs) are natu

273 Tissue inhibitors of metalloproteinases (TIMPs) are plei

274 The four tissue inhibitors of metalloproteinases (TIMPs) are pote

275 sion of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) during t

276 The tissue inhibitors of metalloproteinases (TIMPs) function

277 The balance of MMPs and tissue inhibitors of metalloproteinases (TIMPs) governs

278 The antiangiogenic function of the tissue inhibitors of metalloproteinases (TIMPs) has been

279 pecific matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the a

280 Tissue inhibitors of metalloproteinases (TIMPs) inhibit

281 Tissue inhibitors of metalloproteinases (TIMPs) inhibit

282 etalloproteinases (MMPs) and the activity of tissue inhibitors of metalloproteinases (TIMPs) is impli

283 vels of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) of HGFs

284 Four tissue inhibitors of metalloproteinases (TIMPs) regulate

285 The tissue inhibitors of metalloproteinases (TIMPs) regulate

286 The avid binding of tissue inhibitors of metalloproteinases (TIMPs) to matri

287 alloproteinases (Mmps) regulated by secreted tissue inhibitors of metalloproteinases (Timps), cleave

288 proteinases (MMPs) and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), in the

289 and binding to their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs), is abno

290 between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), leading

291 2)-induced decrease in lymphocyte-associated tissue inhibitors of metalloproteinases (TIMPs), resulti

292 Tissue inhibitors of metalloproteinases (TIMPs), the end

293 To understand the regulation of MMP-10 by tissue inhibitors of metalloproteinases (TIMPs), we have

294 GFs) and the expression of selected MMPs and tissue inhibitors of metalloproteinases (TIMPs).

295 at are regulated, in part, by the endogenous tissue inhibitors of metalloproteinases (TIMPs).

296 inases (MMPs) and their specific inhibitors, tissue inhibitors of metalloproteinases (TIMPs).

297 eem to have a major role in the secretion of tissue inhibitors of metalloproteinases (TIMPs).

298 metalloproteinases (MMPs), their inhibitors (tissue inhibitors of metalloproteinases; TIMPs), and the

299 s may be an effective method for discovering tissue inhibitor of metalloproteinase variants that disc

300 nes involved in tumor cell migration such as tissue inhibitors of metalloproteinases, were also incre